⚠ Evidence warning: Clinical trials or other evidence do not support the claims that women with estrogen-receptor-positive breast cancer history can use black cohosh under an oncologist's supervision and that the scientific consensus is unambiguously that it is not estrogenic. This page keeps it as a report of what people, websites or other media say.

Black Cohosh for Hormonal Balance (Non-Estrogenic Mechanism)

Hormonal Balance — scientific infographic poster

The single most important — and most commonly misunderstood — fact about Black Cohosh is that, in most studies, it does not behave like a phytoestrogen. For most of the twentieth century, the herb was assumed to act like soy isoflavones or red clover — binding weakly to estrogen receptors, producing a partial-agonist effect that mimicked low-dose estrogen. That model was largely set aside after a series of rigorous receptor-binding, gene-expression, and animal-model studies between 2002 and 2008, most notably the Burdette 2003 finding that Black Cohosh extract acts as a mixed competitive ligand at the serotonin 5-HT7 receptor and showed no estrogen-like effect in ovariectomized rats; a few studies still report some estrogen-like effects, so the evidence is mixed rather than settled. The corrected mechanism is multi-target neurotransmitter modulation by the triterpene glycosides actein, 23-epi-26-deoxyactein, and cimicifugoside, with secondary contributions from cinnamic-acid esters. This distinction is why Black Cohosh has been studied in women with a history of estrogen-receptor-positive breast cancer, a group in whom true phytoestrogens raise concern; a German medical-records study of 18,861 breast-cancer patients found no increase in recurrence among the 1,102 who took an isopropanolic extract (see below). Clinically, this distinction matters enormously: women with estrogen-receptor-positive breast cancer history can use Black Cohosh under their oncologist's supervision in a way that they cannot use any true phytoestrogen.


Table of Contents

  1. The Phytoestrogen Myth — How It Started, How It Ended
  2. The Burdette 2003 Serotonin-Receptor Paper
  3. The Receptor-Binding Evidence (ER-alpha, ER-beta, MCF-7, Uterotrophic)
  4. Triterpene Glycosides as the Active Constituents
  5. Serotonergic Mechanism (5-HT7, 5-HT1A)
  6. Dopaminergic and Opioid-Receptor Mechanisms
  7. Effects on the Hypothalamic-Pituitary-Ovarian (HPO) Axis (Follicle-Stimulating Hormone, Luteinizing Hormone, Estradiol, Prolactin)
  8. The KNDy Neuron Model and Why It Fits Black Cohosh
  9. Implications for Breast-Cancer Survivors
  10. What Black Cohosh Does Not Do (Genitourinary Symptoms, Bone — Mostly)
  11. What the Liver Reports Show
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Phytoestrogen Myth — How It Started, How It Ended

The "Black Cohosh is a phytoestrogen" idea originated in the 1980s, when European laboratory work suggested that crude Black Cohosh extracts had estrogen-like activity in some in vitro and animal-model assays. The compound formononetin — an isoflavonoid found in trace amounts in some Black Cohosh preparations — was identified as a possible candidate for the estrogenic activity. The story was clean, mechanistically appealing, and quickly absorbed into the herbal-medicine literature: a North American herb whose traditional use for menopausal symptoms made sense because it was a mild plant estrogen, like soy.

The story began to unravel in the mid-1990s when more careful analyses found that formononetin content in authenticated Actaea racemosa is too low to account for any clinical estrogenic effect — and that several of the original "estrogenic" Black Cohosh samples had been adulterated with red clover (which is genuinely high in formononetin). Receptor-binding studies with purified triterpene glycosides showed no measurable affinity for ER-alpha or ER-beta, although one 2007 study (Bolle) found that a fat-soluble sub-fraction of an extract switched on the human estrogen receptor alpha in a yeast test. Gene-expression studies of estrogen-responsive cells exposed to Black Cohosh extract showed no induction of the expected estrogen-target genes. The Wuttke group's 2003 ovariectomized-rat model showed no uterotrophic effect (a sensitive in vivo assay for estrogen activity).

The capstone study was Burdette 2003 (Journal of Agricultural and Food Chemistry), which found no change in uterine weight or vaginal cells in ovariectomized rats given a 40% 2-propanol extract, then tested the extract against 10 serotonin receptor subtypes and found strong binding to 5-HT1A, 5-HT1D and 5-HT7, most potently at 5-HT7. Subsequent work by the Bolton laboratory at the University of Illinois at Chicago, the Wuttke laboratory at Göttingen, and several other groups built out a much more textured mechanism map involving serotonergic, dopaminergic, GABAergic, and mu-opioid pathways. The evidence on estrogen-like activity is mixed rather than settled: most receptor and hormone studies find no estrogen-like action, but a 2003 trial by the Wuttke group found more surface cells in vaginal smears with both a black cohosh extract and conjugated estrogens and proposed that the extract has selective estrogen receptor modulator (SERM) activity, and Bolle 2007 found estrogen-receptor activation by one sub-fraction in a yeast test. The current scientific consensus, codified in the European Medicines Agency monograph and the German Commission E review, is unambiguous: Black Cohosh is not estrogenic.

The phytoestrogen description persists in consumer-facing materials, on supplement labels, and in many older medical and herbal-medicine textbooks because the correction is not commercially convenient — "natural plant estrogen for menopause" is a simpler marketing message than "multi-target serotonergic modulator with bone-protective triterpene glycosides."

Back to Table of Contents

The Burdette 2003 Serotonin-Receptor Paper

Joanna Burdette and colleagues at the Bolton laboratory at the University of Illinois at Chicago published the paper that fundamentally changed the Black Cohosh mechanism story in Journal of Agricultural and Food Chemistry in 2003. The study first gave ovariectomized rats a 40% 2-propanol extract of Actaea racemosa rhizome for 2 weeks, with or without estradiol: there was no effect on uterine weight or on vaginal cell cornification, so in this model the extract showed neither estrogenic nor antiestrogenic properties. The same extract was then tested against 10 subtypes of the human serotonin (5-HT) receptor.

The extract showed strong binding to the 5-HT1A, 5-HT1D and 5-HT7 subtypes, and blocked binding at the human 5-HT7 receptor (IC50 2.4 µg/mL) more potently than at the rat 5-HT1A receptor (IC50 13.9 µg/mL). A methanol extract behaved as a mixed competitive ligand of 5-HT7 and raised cyclic AMP in cells carrying the receptor, which the authors read as partial agonism. The 5-HT7 receptor is particularly relevant because it is expressed in the hypothalamic preoptic area — the brain region that regulates core body temperature setpoint and that is centrally involved in the generation of hot flashes. Paroxetine, venlafaxine, and other selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors reduce hot-flash frequency by approximately 30–50% in clinical trials — and these drugs work by increasing synaptic serotonin, which then engages serotonin receptors including 5-HT7.

The authors concluded that reductions in hot flashes in some women taking black cohosh “may not be due to estrogenic properties” and that serotonin receptors are other possible targets. The paper's title describes a serotonin-receptor ligand; the SERM idea comes from a different 2003 trial by the Wuttke group (see below).

Back to Table of Contents

The Receptor-Binding Evidence (ER-alpha, ER-beta, MCF-7, Uterotrophic)

The case that Black Cohosh is not estrogenic rests on several lines of evidence, and a few studies point the other way:

The convergence across six independent assay systems — three in vitro, two animal-model, one human clinical — is what gives the non-estrogenic conclusion its weight.

Most of these assay systems point away from an estrogen-like action, but the Wuttke 2003 vaginal-cell finding and the Bolle 2007 yeast result mean the evidence is mixed rather than unanimous.

Back to Table of Contents

Triterpene Glycosides as the Active Constituents

Phytochemical fractionation studies have identified the triterpene glycosides as the dominant pharmacologically active class in Actaea racemosa rhizome. The principal compounds are:

The triterpene glycosides are not water-soluble; they extract preferentially into iso-propanol, ethanol, or methylene chloride. This is one reason an isopropanolic black cohosh extract has the most-studied pharmacological profile — the extraction solvent matches the solubility profile of the active compounds. (BNO 1055, used in the Wuttke 2003 and Hernández Muñoz 2003 trials, is a different extract.) Aqueous teas and water-extracted preparations contain a different and probably less active phytochemical profile.

The cinnamic-acid esters (fukinolic acid, cimicifugic acids A–F) are secondary contributors. Some in vitro work suggests these compounds have antioxidant and anti-inflammatory activity that may contribute to the overall clinical effect, but they are not the primary mediators of the serotonergic and hormonal effects.

Back to Table of Contents

Serotonergic Mechanism (5-HT7, 5-HT1A)

The serotonergic mechanism is the most-studied and most-likely-relevant for the clinical effect on hot flashes. The relevant pharmacology:

The 5-HT7 binding has been proposed as the link to hot flashes: the hypothalamic preoptic area integrates serotonergic, noradrenergic, and KNDy-neuron signals to set the core temperature setpoint. The narrowed thermoneutral zone characteristic of menopause — where small upward shifts in core temperature trigger a vasodilation-and-sweating heat-dissipation cascade that the patient experiences as a hot flash — is partly serotonin-mediated. Drugs that increase serotonergic tone (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors) widen the thermoneutral zone and reduce hot flashes. The proposal is that Black Cohosh, by partially agonizing 5-HT7 in the preoptic area, produces a similar widening with a different molecular mechanism; this has not been shown in people.

The clinical results so far do not match the laboratory picture. A 2012 Cochrane review (Leach and Moore) pooled 16 randomised trials with 2,027 perimenopausal or postmenopausal women, who took a median of 40 mg of black cohosh a day for an average of 23 weeks. In the three trials (393 women) that counted hot flushes, black cohosh did not differ significantly from placebo (a difference of 0.07 flushes a day), and menopausal symptom scores did not differ in four trials (357 women). Hormone therapy reduced symptom scores more than black cohosh did. The reviewers found “insufficient evidence to support the use of black cohosh for menopausal symptoms”, noted that the quality of the trials was generally unclear, and judged further studies justified.

Back to Table of Contents

Dopaminergic and Opioid-Receptor Mechanisms

Dopaminergic activity: In vitro studies (Jarry 2003; Powell 2008) have documented Black Cohosh extract binding to dopamine D2 receptors with moderate affinity. The D2 receptor is the primary target of prolactin-suppressing drugs like bromocriptine and cabergoline (D2 agonism on lactotrophs in the anterior pituitary suppresses prolactin secretion). Some clinical studies have documented mild prolactin reduction in women on Black Cohosh, consistent with weak D2 agonism. The dopaminergic effect may also contribute to mood modulation through mesolimbic and tuberoinfundibular pathways. The clinical magnitude is modest — Black Cohosh is not a substitute for cabergoline in true hyperprolactinemia and is not a clinically significant antipsychotic-effect modifier.

Mu-opioid receptor activity: Reame and colleagues (2008) studied postmenopausal women before and after 12 weeks of unblinded treatment with a black cohosh supplement at 40 mg a day. Brain scans with a tracer that binds mu-opioid receptors (positron emission tomography, PET, in 5 women) showed mu-opioid receptor binding rising by 10% to 61% in several brain regions involved in emotion and thinking, and a naloxone challenge (6 women) changed luteinizing hormone pulses; the authors read both as a central opioid action. The clinical significance is debated. The opioid-receptor hypothesis is mechanistically interesting because the hypothalamic KNDy-neuron system (kisspeptin/neurokinin B/dynorphin) that is now understood as the central regulator of vasomotor symptoms is itself opioid-modulated — dynorphin is a kappa-opioid agonist and is a key inhibitory signal in the KNDy negative-feedback loop. A drug that engages opioid receptors in this circuit could plausibly modulate the entire vasomotor-symptom-generating system. This remains an active research area without clear clinical-evidence translation yet.

The opioid hypothesis also raises a safety question about possible opioid-receptor desensitization, tolerance, or withdrawal with chronic Black Cohosh use. The clinical-trial data through 12 months of use show no withdrawal syndrome on discontinuation and no progressive tolerance, but the data do not address all the questions that the opioid mechanism raises. In the trials pooled by the 2012 Cochrane review, treatment lasted 23 weeks on average, so use beyond a year has been studied less. This is one reason that clinically the recommendation is to limit Black Cohosh courses to 6–12 months with monitoring rather than indefinite use.

Back to Table of Contents

Effects on the Hypothalamic-Pituitary-Ovarian (HPO) Axis (Follicle-Stimulating Hormone, Luteinizing Hormone, Estradiol, Prolactin)

If Black Cohosh were genuinely estrogenic, you would expect to see negative-feedback suppression of follicle-stimulating hormone (FSH) (which is elevated in postmenopausal women due to loss of ovarian estrogen feedback). You would expect to see suppression of luteinizing hormone (LH) for the same reason. You would expect to see measurable serum estradiol elevation if the herb itself or its metabolites were binding circulating sex-hormone-binding globulin or being measured in the estradiol immunoassay. None of these are observed.

Two trials give a sense of the numbers. In Liske 2002, perimenopausal and postmenopausal women took 39 mg or 127.3 mg a day of an isopropanolic extract for 24 weeks: symptoms fell at both doses (responder rates 70% and 72%), the higher dose did no better on any end point, and vaginal cytology and gynecologically relevant hormones showed no significant change; the study had no placebo group. In Bai 2007, a double-blind trial, 244 Chinese women aged 40–60 took the isopropanolic extract (40 mg of crude herb a day) or tibolone 2.5 mg a day for 3 months: the Kupperman Menopause Index fell from 24.7 to 7.7 with black cohosh and to 7.5 with tibolone, which the authors judged non-inferior; adverse events were less frequent with black cohosh, and none of the postmenopausal women on black cohosh had vaginal bleeding, against 17 cases on tibolone.

Because these hormone levels did not change in the trials, hormone tests do not track Black Cohosh's effect; the safety concern that has been reported is liver injury (see the liver section below). Symptom response and liver-function monitoring are the relevant clinical parameters. See the Hormone Panel page for the relevant baseline-assessment context.

Back to Table of Contents

The KNDy Neuron Model and Why It Fits Black Cohosh

The current best model of hot-flash generation centers on the KNDy neurons — arcuate-nucleus neurons that co-express kisspeptin, neurokinin B, and dynorphin. In premenopausal women, these neurons receive negative-feedback signals from circulating estrogen, which keeps their tonic firing rate suppressed. After menopause, estrogen drops, the KNDy neurons hypertrophy (documented in human autopsy studies), and their now-disinhibited firing produces a heightened input to the hypothalamic thermoregulatory center.

The KNDy neurons release neurokinin B (an NK3 receptor agonist) onto the preoptic-area thermoregulatory neurons, which narrows the thermoneutral zone and triggers a heat-dissipation cascade (cutaneous vasodilation, sweating) at lower-than-normal core-temperature triggers. The clinical proof of this mechanism came in 2019–2020 with the demonstration that NK3-receptor antagonists (fezolinetant, elinzanetant) reduce hot-flash frequency by 60–75% in randomized trials — an effect size approaching that of systemic estrogen. Fezolinetant was approved by the U.S. Food and Drug Administration (FDA) in 2023 for moderate-to-severe vasomotor symptoms; elinzanetant followed on October 24, 2025.

The KNDy model is relevant to Black Cohosh because the proposed serotonergic, dopaminergic, and opioid mechanisms of Black Cohosh all converge on the KNDy neurons and their downstream targets. 5-HT7 stimulation in the preoptic area widens the thermoneutral zone. D2 agonism in the arcuate nucleus modulates KNDy firing. Mu-opioid engagement parallels endogenous dynorphin's inhibitory role within the KNDy cell itself. The molecular targets are different from NK3 antagonism; whether the system-level effect is similar — restoration of a wider thermoneutral zone — has not been shown, and the 2012 Cochrane review found no significant difference between black cohosh and placebo in daily hot flushes.

In this converging-pathway model, both Black Cohosh and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors act on the serotonergic input to the same hypothalamic circuit, by different molecular mechanisms. The 2023 position statement of the North American Menopause Society (NAMS) lists these drugs among the recommended nonhormone options for hot flashes (Level I evidence) and lists supplements and herbal remedies as not recommended (Levels I–II).

Back to Table of Contents

Implications for Breast-Cancer Survivors

The non-estrogenic mechanism is the single most clinically consequential fact about Black Cohosh because it is why Black Cohosh has been studied for vasomotor symptoms (hot flashes and sweats) in women with a personal history of estrogen-receptor-positive breast cancer.

The evidence so far:

In the breast-cancer studies above, the extract was taken for 6 to 12 months alongside tamoxifen. The safety concern reported for Black Cohosh is liver injury (see the liver section below); some chemotherapy drugs can also harm the liver. The principal monitoring requirement is liver function (the hepatotoxicity warning applies with extra force in patients who may be on hepatotoxic chemotherapy). See the Menopause & Hot Flashes deep-dive for the trial-specific evidence.

Back to Table of Contents

What Black Cohosh Does Not Do (Genitourinary Symptoms, Bone — Mostly)

Areas where Black Cohosh has not been shown to help much:

Back to Table of Contents

What the Liver Reports Show

In 2008 the Dietary Supplement Information Expert Committee of the United States Pharmacopeia (USP) reviewed safety information on black cohosh products, after regulators in Australia, Canada and the European Union had issued statements on a “potential association” with liver damage. The committee analysed 30 non-duplicate reports of liver damage, gathered from the European Medicines Agency, Health Canada, the Australian Therapeutic Goods Administration and the US Food and Drug Administration, using the Naranjo causality scale. All 30 were rated “possible” causality; none were rated “probable” or “certain”. Animal toxicology and pharmacokinetic data showed nothing unfavourable. The committee nevertheless decided that black cohosh products should carry a cautionary label statement — a change from its 2002 decision, which required none.

Yellowing of the skin or eyes (jaundice), dark urine and pain in the upper right belly are signs of liver injury that hospitals treat as urgent.

Back to Table of Contents

Key Research Papers

  1. Burdette JE, Liu J, Chen SN et al. (2003). Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. Journal of Agricultural and Food Chemistry 51(19):5661-70. — PubMed PMID: 12952416
  2. Liu J, Burdette JE, Xu H et al. (2001). Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. Journal of Agricultural and Food Chemistry 49(5):2472-9. — PubMed PMID: 11368622
  3. Wuttke W, Jarry H, Becker T et al. (2003). Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? Maturitas 44 Suppl 1:S9-20. — PubMed PMID: 12609555
  4. Bodinet C, Freudenstein J (2002). Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Research and Treatment 76(1):1-10. — PubMed PMID: 12408370
  5. Hostanska K, Nisslein T, Freudenstein J et al. (2004). Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Research and Treatment 84(2):151-60. — PubMed PMID: 14999145
  6. Powell SL et al. (2008). In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent. Journal of Agricultural and Food Chemistry 56(24):11718-26. — PubMed PMID: 19049296
  7. Reame NE et al. (2008). Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 15(5):832-40. — PubMed PMID: 18521048
  8. Jarry H, Metten M, Spengler B et al. (2003). In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas 44 Suppl 1:S31-8. — PubMed PMID: 12609557
  9. Bolle P, Mastrangelo S, Perrone F et al. (2007). Estrogen-like effect of a Cimicifuga racemosa extract sub-fraction as assessed by in vivo, ex vivo and in vitro assays. Journal of Steroid Biochemistry and Molecular Biology 107(3-5):262-9. — PubMed PMID: 17689956
  10. Ruhlen RL et al. (2007). Black cohosh: insights into its mechanism(s) of action. Integrative Medicine Insights 2:21-32. — PubMed
  11. Rostock M, Fischer J, Mumm A et al. (2011). Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints — a prospective observational study. Gynecological Endocrinology 27(10):844-8. — PubMed PMID: 21231853
  12. Henneicke-von Zepelin HH, Meden H, Kostev K et al. (2007). Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. International Journal of Clinical Pharmacology and Therapeutics 45(3):143-54. — PubMed PMID: 17416109
  13. Wuttke W, Seidlová-Wuttke D, Gorkow C (2003). The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 44 Suppl 1:S67-77. — PubMed PMID: 12609561
  14. Hernández Muñoz G, Pluchino S (2003). Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 44 Suppl 1:S59-65. — PubMed PMID: 12609560
  15. Liske E, Hänggi W, Henneicke-von Zepelin HH et al. (2002). Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. Journal of Women's Health & Gender-Based Medicine 11(2):163-74. — PubMed PMID: 11975864
  16. Bai W, Henneicke-von Zepelin HH, Wang S et al. (2007). Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 58(1):31-41. — PubMed PMID: 17587516
  17. Leach MJ, Moore V (2012). Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews 2012(9):CD007244. — PubMed PMID: 22972105
  18. Mahady GB, Low Dog T, Barrett ML et al. (2008). United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 15(4 Pt 1):628-38. — PubMed PMID: 18340277
  19. The North American Menopause Society (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause 30(6):573-590. — PubMed PMID: 37252752

PubMed Topic Searches

  1. PubMed: Black cohosh receptor binding
  2. PubMed: Cimicifuga 5-HT7 mechanism
  3. PubMed: Actein triterpene glycoside
  4. PubMed: Black cohosh breast cancer safety
  5. PubMed: KNDy / NK3 menopause

Back to Table of Contents

Connections

Back to Table of Contents